vs
Side-by-side financial comparison of Blackstone Inc. (BX) and Edwards Lifesciences (EW). Click either name above to swap in a different company.
Blackstone Inc. is the larger business by last-quarter revenue ($3.3B vs $1.6B, roughly 2.0× Edwards Lifesciences). Blackstone Inc. runs the higher net margin — 36.7% vs 23.1%, a 13.7% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs -9.1%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs 8.5%).
Blackstone Inc. is an American alternative investment management company based in New York City. It was founded in 1985 as a mergers and acquisitions firm by Peter Peterson and Stephen Schwarzman, who had previously worked together at Lehman Brothers. Blackstone's private equity business has been one of the largest investors in leveraged buyouts in the last three decades, while its real estate business has actively acquired commercial real estate across the globe.
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.
BX vs EW — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.3B | $1.6B |
| Net Profit | $1.2B | $380.7M |
| Gross Margin | — | 78.0% |
| Operating Margin | — | 1.8% |
| Net Margin | 36.7% | 23.1% |
| Revenue YoY | -9.1% | 16.7% |
| Net Profit YoY | -3.9% | 6.8% |
| EPS (diluted) | $0.80 | $0.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $3.3B | $1.6B | ||
| Q4 25 | $4.4B | $1.6B | ||
| Q3 25 | $3.1B | $1.6B | ||
| Q2 25 | $3.7B | $1.5B | ||
| Q1 25 | $3.3B | $1.4B | ||
| Q4 24 | $3.1B | $1.4B | ||
| Q3 24 | $3.7B | $1.4B | ||
| Q2 24 | $2.8B | $1.4B |
| Q1 26 | $1.2B | $380.7M | ||
| Q4 25 | $1.0B | $91.2M | ||
| Q3 25 | $624.9M | $291.1M | ||
| Q2 25 | $764.2M | $333.2M | ||
| Q1 25 | $614.9M | $358.0M | ||
| Q4 24 | $703.9M | $385.6M | ||
| Q3 24 | $780.8M | $3.1B | ||
| Q2 24 | $444.4M | $366.3M |
| Q1 26 | — | 78.0% | ||
| Q4 25 | — | 78.1% | ||
| Q3 25 | — | 77.8% | ||
| Q2 25 | — | 77.5% | ||
| Q1 25 | — | 78.7% | ||
| Q4 24 | — | 78.9% | ||
| Q3 24 | — | 80.6% | ||
| Q2 24 | — | 79.9% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | 54.1% | 9.6% | ||
| Q3 25 | 46.8% | 19.8% | ||
| Q2 25 | 51.6% | 26.8% | ||
| Q1 25 | 44.2% | 27.9% | ||
| Q4 24 | 50.6% | 22.6% | ||
| Q3 24 | 49.4% | 25.9% | ||
| Q2 24 | 43.2% | 26.8% |
| Q1 26 | 36.7% | 23.1% | ||
| Q4 25 | 23.3% | 5.8% | ||
| Q3 25 | 20.2% | 18.7% | ||
| Q2 25 | 20.6% | 21.7% | ||
| Q1 25 | 18.7% | 25.3% | ||
| Q4 24 | 22.8% | 27.8% | ||
| Q3 24 | 21.3% | 226.7% | ||
| Q2 24 | 15.9% | 26.7% |
| Q1 26 | $0.80 | $0.66 | ||
| Q4 25 | $1.29 | $0.16 | ||
| Q3 25 | $0.80 | $0.50 | ||
| Q2 25 | $0.98 | $0.56 | ||
| Q1 25 | $0.80 | $0.61 | ||
| Q4 24 | $0.91 | $0.65 | ||
| Q3 24 | $1.02 | $5.13 | ||
| Q2 24 | $0.58 | $0.61 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $18.5B | — |
| Total Assets | $45.3B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.6B | $4.2B | ||
| Q3 25 | $2.4B | $3.8B | ||
| Q2 25 | $2.2B | $4.1B | ||
| Q1 25 | $2.4B | $3.9B | ||
| Q4 24 | $2.0B | $4.0B | ||
| Q3 24 | $2.4B | $4.4B | ||
| Q2 24 | $2.4B | $2.0B |
| Q1 26 | — | — | ||
| Q4 25 | $12.6B | — | ||
| Q3 25 | $12.1B | — | ||
| Q2 25 | $12.1B | — | ||
| Q1 25 | $12.6B | — | ||
| Q4 24 | $11.5B | — | ||
| Q3 24 | $10.9B | — | ||
| Q2 24 | $10.8B | — |
| Q1 26 | $18.5B | — | ||
| Q4 25 | $8.7B | $10.3B | ||
| Q3 25 | $8.4B | $10.2B | ||
| Q2 25 | $8.4B | $10.5B | ||
| Q1 25 | $8.0B | $10.1B | ||
| Q4 24 | $8.2B | $10.0B | ||
| Q3 24 | $7.0B | $9.5B | ||
| Q2 24 | $6.8B | $7.4B |
| Q1 26 | $45.3B | — | ||
| Q4 25 | $47.7B | $13.7B | ||
| Q3 25 | $46.6B | $13.3B | ||
| Q2 25 | $45.4B | $13.5B | ||
| Q1 25 | $45.3B | $13.0B | ||
| Q4 24 | $43.5B | $13.1B | ||
| Q3 24 | $42.6B | $13.0B | ||
| Q2 24 | $40.6B | $10.1B |
| Q1 26 | — | — | ||
| Q4 25 | 1.45× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.58× | — | ||
| Q4 24 | 1.40× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.58× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BX
| Management and Advisory Fees, Net | $1.9B | 58% |
| Realized | $562.0M | 17% |
| Other | $368.1M | 11% |
| Unrealized | $263.2M | 8% |
| Incentive Fees | $191.8M | 6% |
EW
Segment breakdown not available.
